Literature DB >> 18195566

Reduced bone mineral density in HIV-infected patients: prevalence and associated factors.

Charles Cazanave1, Michel Dupon, Valérie Lavignolle-Aurillac, Nicole Barthe, Sylvie Lawson-Ayayi, Nadia Mehsen, Patrick Mercié, Phillipe Morlat, Rodolphe Thiébaut, François Dabis.   

Abstract

BACKGROUND: There is a high prevalence of bone demineralization among HIV-infected patients but mechanisms of alteration of bone turnover are still unclear and it is thought to be multifactorial.
METHODS: A cross-sectional survey of 492 HIV-infected patients within the Aquitaine cohort estimated the prevalence of osteoporosis/osteopenia and investigated associated factors. Bone mineral density of total body, lumbar spine and femoral neck was measured by dual-energy X-ray absorptiometry. Multivariable analyses of the association with HIV disease status, treatment and anthropometric parameters were stratified according to gender.
RESULTS: Median age was 43 years (interquartile range, 38-50); 73% were male; 19.7% patients had reached AIDS, 93.1% were treated with HAART; and 28.5% had lipodystrophy. Based on World Health Organization criteria, osteopenia was diagnosed in 54.6% of men [95% confidence interval (CI), 49.4-59.7) and 51.1% of women (95% CI, 42.6-59.6) and osteoporosis in 33.7% of men (95% CI, 28.8-38.6) and 8.3% of women (95% CI, 3.6-13.9). Using a polytomous logistic regression, older age, homosexual transmission group, low body mass index and low HIV plasma viral load were associated with the diagnosis of bone abnormalities in men, whereas older age and low CD4 lymphocyte count nadir were independently associated with osteoporosis/osteopenia in women. The use of HAART was not related to osteoporosis after adjustment (P = 0.58).
CONCLUSIONS: This cohort-based survey showed a high prevalence of osteopenia and osteoporosis of multifactorial origin. Mechanisms and consequences of these bone disorders need to be investigated.

Entities:  

Mesh:

Year:  2008        PMID: 18195566     DOI: 10.1097/QAD.0b013e3282f423dd

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  75 in total

1.  Bone disease in HIV infection.

Authors:  Maristella Francesca Saccomanno; Adriana Ammassari
Journal:  Clin Cases Miner Bone Metab       Date:  2011-01

Review 2.  Care of the human immunodeficiency virus-infected menopausal woman.

Authors:  Helen Elizabeth Cejtin
Journal:  Am J Obstet Gynecol       Date:  2011-12-30       Impact factor: 8.661

3.  Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation.

Authors:  Philip M Grant; Douglas Kitch; Grace A McComsey; Michael P Dube; Richard Haubrich; Jeannie Huang; Sharon Riddler; Pablo Tebas; Andrew R Zolopa; Ann C Collier; Todd T Brown
Journal:  Clin Infect Dis       Date:  2013-08-13       Impact factor: 9.079

4.  Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Kathleen Mulligan; David V Glidden; Peter L Anderson; Albert Liu; Vanessa McMahan; Pedro Gonzales; Maria Esther Ramirez-Cardich; Sirianong Namwongprom; Piotr Chodacki; Laura Maria Carvalo de Mendonca; Furong Wang; Javier R Lama; Suwat Chariyalertsak; Juan Vicente Guanira; Susan Buchbinder; Linda-Gail Bekker; Mauro Schechter; Valdilea G Veloso; Robert M Grant
Journal:  Clin Infect Dis       Date:  2015-04-23       Impact factor: 9.079

5.  Prevalence of abnormal bone mineral density in hiv-positive patients in ibadan, Nigeria.

Authors:  T O Alonge; V N Okoje-Adesomoju; O M Atalabi; H A Obamuyide; D Olaleye; I F Adewole
Journal:  J West Afr Coll Surg       Date:  2013 Oct-Dec

Review 6.  Update on tenofovir toxicity in the kidney.

Authors:  Andrew M Hall
Journal:  Pediatr Nephrol       Date:  2012-08-10       Impact factor: 3.714

7.  Relationships between inflammation, immune activation, and bone health among HIV-infected adults on stable antiretroviral therapy.

Authors:  Kristine M Erlandson; Maryann OʼRiordan; Danielle Labbato; Grace A McComsey
Journal:  J Acquir Immune Defic Syndr       Date:  2014-03-01       Impact factor: 3.731

8.  A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis.

Authors:  Jeannie Huang; Linda Meixner; Susan Fernandez; J Allen McCutchan
Journal:  AIDS       Date:  2009-01-02       Impact factor: 4.177

9.  Increased risk of fragility fractures among HIV infected compared to uninfected male veterans.

Authors:  Julie A Womack; Joseph L Goulet; Cynthia Gibert; Cynthia Brandt; Chung Chou Chang; Barbara Gulanski; Liana Fraenkel; Kristin Mattocks; David Rimland; Maria C Rodriguez-Barradas; Janet Tate; Michael T Yin; Amy C Justice
Journal:  PLoS One       Date:  2011-02-16       Impact factor: 3.240

10.  High frequency of hypothalamic-pituitary-adrenal axis dysfunction after local corticosteroid injection in HIV-infected patients on protease inhibitor therapy.

Authors:  Emily P Hyle; Brian R Wood; Elke S Backman; Farzad Noubary; Janice Hwang; Zhigang Lu; Elena Losina; Rochelle P Walensky; Rajesh T Gandhi
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-15       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.